Organon To Open Cambridge, Mass. R&D Facility In Early 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Akzo Nobel plans to integrate its pharmaceutical businesses, Organon and Diosynth, into a single entity called Organon. The restructuring is part of Akzo's focus on short-term issues with its pharma division.
You may also be interested in...
Biotech Manufacturing May Be Key To R&D Deals, Organon Says
Organon hopes to use its biologics manufacturing capacity to attract biotech partners, the company said during the Akzo Nobel fall analysts meeting in London Nov. 15
Biotech Manufacturing May Be Key To R&D Deals, Organon Says
Organon hopes to use its biologics manufacturing capacity to attract biotech partners, the company said during the Akzo Nobel fall analysts meeting in London Nov. 15
Organon Pharma Focus Is "Short Term": Strategic Decisions Later
Akzo Nobel wants to "fix pharma first" before it makes any decisions about long-term strategy in Rx sector, company says. Sales of Follistim are being held back by supply problems following shutdown of West Orange, N.J. plant.